Exelixis (NASDAQ:EXEL) Shares Up 6.4%
Shares of Exelixis, Inc. (NASDAQ:EXEL) shot up 6.4% on Tuesday . The company traded as high as $19.72 and last traded at $19.65, 4,666,791 shares changed hands during trading. An increase of 29% from the average session volume of 3,628,088 shares. The stock had previously closed at $18.47.
EXEL has been the topic of a number of research reports. ValuEngine raised Exelixis from a “sell” rating to a “hold” rating in a report on Tuesday, December 3rd. SunTrust Banks initiated coverage on Exelixis in a report on Monday. They issued a “buy” rating and a $31.00 price objective on the stock. BidaskClub lowered Exelixis from a “sell” rating to a “strong sell” rating in a report on Tuesday, January 7th. BMO Capital Markets decreased their price objective on Exelixis from $23.00 to $19.00 and set a “market perform” rating on the stock in a report on Tuesday, October 8th. Finally, Bank of America reaffirmed a “buy” rating and issued a $21.00 price objective (down from $22.00) on shares of Exelixis in a report on Monday. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating and eight have issued a buy rating to the company’s stock. Exelixis currently has an average rating of “Buy” and a consensus price target of $25.91.
The company has a debt-to-equity ratio of 0.01, a quick ratio of 6.80 and a current ratio of 6.89. The business has a fifty day simple moving average of $17.79 and a 200 day simple moving average of $18.64. The stock has a market capitalization of $5.57 billion, a price-to-earnings ratio of 13.74, a price-to-earnings-growth ratio of 2.43 and a beta of 1.74.
In other news, Director Alan M. Garber sold 86,956 shares of the company’s stock in a transaction on Tuesday, January 7th. The stock was sold at an average price of $18.01, for a total transaction of $1,566,077.56. Following the completion of the sale, the director now directly owns 91,329 shares in the company, valued at approximately $1,644,835.29. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CMO Gisela Schwab sold 50,000 shares of the company’s stock in a transaction on Tuesday, January 7th. The shares were sold at an average price of $17.96, for a total value of $898,000.00. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 286,956 shares of company stock valued at $5,040,078. Corporate insiders own 4.50% of the company’s stock.
Large investors have recently added to or reduced their stakes in the company. Voya Investment Management LLC lifted its position in shares of Exelixis by 3.1% during the 3rd quarter. Voya Investment Management LLC now owns 283,322 shares of the biotechnology company’s stock valued at $5,010,000 after acquiring an additional 8,551 shares during the period. Virtu Financial LLC lifted its position in shares of Exelixis by 107.5% during the 3rd quarter. Virtu Financial LLC now owns 55,353 shares of the biotechnology company’s stock valued at $979,000 after acquiring an additional 28,681 shares during the period. Nomura Holdings Inc. lifted its position in shares of Exelixis by 52.3% during the 3rd quarter. Nomura Holdings Inc. now owns 49,500 shares of the biotechnology company’s stock valued at $880,000 after acquiring an additional 17,000 shares during the period. Symmetry Partners LLC bought a new stake in shares of Exelixis during the 3rd quarter valued at $185,000. Finally, Squarepoint Ops LLC lifted its position in shares of Exelixis by 174.7% during the 3rd quarter. Squarepoint Ops LLC now owns 305,778 shares of the biotechnology company’s stock valued at $5,408,000 after acquiring an additional 194,446 shares during the period. Hedge funds and other institutional investors own 77.05% of the company’s stock.
Exelixis Company Profile (NASDAQ:EXEL)
Exelixis, Inc, an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer.
Featured Story: Balanced Fund
Receive News & Ratings for Exelixis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exelixis and related companies with MarketBeat.com's FREE daily email newsletter.